We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

Comparative Effectiveness Trial for Diabetic Macular Edema Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network

Lee M. Jampol, MD1; Adam R. Glassman, MS2; Neil M. Bressler, MD3,4
[+] Author Affiliations
1Feinberg School of Medicine, Northwestern University, Chicago, Illinois
2Jaeb Center for Health Research, Tampa, Florida
3Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
4Editor in Chief, JAMA Ophthalmology
JAMA Ophthalmol. 2015;133(9):983-984. doi:10.1001/jamaophthalmol.2015.1880.
Text Size: A A A
Published online


This Viewpoint discusses the early findings of the Diabetic Retinopathy Clinical Research Network, which is comparing the effectiveness of aflibercept, bevacizumab, and ranibizumab in patients with diabetic macular edema.

Thickening of the center of the retina from diabetes mellitus, diabetic macular edema (DME), is a common cause of vision impairment and blindness in the United States.1 Diabetic macular edema is associated with increased intraocular levels of vascular endothelial growth factor (VEGF).2 Vascular endothelial growth factor also can cause proliferation of new vasculature on the surface of the retina (neovascularization of the disc or elsewhere), termed proliferative diabetic retinopathy. Left untreated, DME or proliferative diabetic retinopathy may damage the retina, causing substantial vision loss.

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

3 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles